These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31364797)

  • 1. A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice.
    Huan Y; Pan X; Peng J; Jia C; Sun S; Bai G; Wang X; Zhou T; Li R; Liu S; Li C; Liu Q; Liu Z; Shen Z
    Diabetes Obes Metab; 2019 Nov; 21(11):2553-2563. PubMed ID: 31364797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
    Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
    Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
    Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
    J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
    Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
    J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
    Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
    Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
    Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
    Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
    Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
    J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
    Konda VR; Desai A; Darland G; Grayson N; Bland JS
    PLoS One; 2014; 9(1):e87848. PubMed ID: 24498211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
    Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
    Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice.
    Jia C; Huan Y; Liu S; Hou S; Sun S; Li C; Liu Q; Jiang Q; Wang Y; Shen Z
    Int J Mol Sci; 2015 May; 16(6):12213-29. PubMed ID: 26035752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
    Kim KR; Lee JH; Kim SJ; Rhee SD; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Biochem Pharmacol; 2006 Aug; 72(4):446-54. PubMed ID: 16797489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystathionine γ lyase-hydrogen sulfide increases peroxisome proliferator-activated receptor γ activity by sulfhydration at C139 site thereby promoting glucose uptake and lipid storage in adipocytes.
    Cai J; Shi X; Wang H; Fan J; Feng Y; Lin X; Yang J; Cui Q; Tang C; Xu G; Geng B
    Biochim Biophys Acta; 2016 May; 1861(5):419-29. PubMed ID: 26946260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.